CEACAM5 and gastric cancer: Although CEA and CA19-9 are frequently used as markers in GC patients, these markers are elevated in less than 40% of patients with advanced GC, and they temporary increase following chemotherapy; therefore, the sensitivity and specificity of assays to detect these markers are insufficient for prognosis [29].